ExicureXCUR
XCUR
About: Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Employees: 5
0
Funds holding %
of 6,759 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1.12% less ownership
Funds ownership: 6.76% [Q1] → 5.64% (-1.12%) [Q2]
21% less funds holding
Funds holding: 19 [Q1] → 15 (-4) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
54% less capital invested
Capital invested by funds: $341K [Q1] → $156K (-$185K) [Q2]
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for XCUR.
Financial journalist opinion
Charts implemented using Lightweight Charts™